Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multinational double blind placebo-controlled, parallel group study to evaluate the efficacy and safety of CCX282B in subjects with moderate to severe Crohn's disease.

Next Previous
Search
Trial Profile

A multinational double blind placebo-controlled, parallel group study to evaluate the efficacy and safety of CCX282B in subjects with moderate to severe Crohn's disease.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 10 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Vercirnon (Primary)
  • Indications Crohn's disease
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms PROTECT-1
  • Sponsors ChemoCentryx

    • Most Recent Events

    • 20 Oct 2014 Results published in a ChemoCentryx media release.
    • 29 Jun 2012 Planned number of patients changed from 423 to 598 as reported by ClinicalTrials.gov.
    • 27 Oct 2010 One-year results have been presented at the United European Gastroenterology Federation meeting according to a ChemoCentryx media release. The results are discussed further within the media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top